Please login to the form below

diffuse large B-cell lymphoma

This page shows the latest diffuse large B-cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

BMS links up with Molecular Templates for oncology research collaboration

MTEM’s pipeline includes a number of oncology-directed assets, such as a first-generation ETB (MT-3724) in phase 2 development for pre-treated diffuse large B-cell lymphoma (DLBCL)

Latest news

FDA approves BMS’ blood cancer CAR T therapy after delay

including diffuse large B-cell lymphoma (DLBCL). ... Novartis’ Kymriah (tisagenlecleucel) was approved soon afterwards, also gaining clearance for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Merck strengthens oncology pipeline with $2.75bn VelosBio deal

resulted in objective clinical responses in 47% of patients with mantle cell lymphoma (MCL) and 80% of patients with diffuse large B-cell lymphoma (DLBCL). ... and diffuse large B-cell lymphoma,” he added.
NICE recommends Roche’s Polivy for B-cell lymphoma

drug conjugate Polivy in combination with Rituxan (rituximab) and bendamustine for the treatment of diffuse large B-cell lymphoma (DLBCL). ... It will be made available from today for patients whose cancer has relapsed or not responded to primary
Gilead swoops on Forty Seven with $4.9bn all-cash deal

Studies have also suggested that blocking CD47 can send some tumour cells into programmed cell death (apoptosis). ... Forty Seven is also testing the drug in patients with non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and three solid tumours –
IMV preps pivotal trials for ovarian cancer T cell therapy

The therapy is being tested alongside Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab) in two phase 2 studies, including an investigator-led trial in patients with advanced-stage diffuse large ... B-cell lymphoma (DLBCL) and another spanning

More from news
Approximately 1 fully matching, plus 87 partially matching documents found.

Latest Intelligence

European biotech: a new generation of leaders emerges

The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with ... Nevertheless, European biotech has reason to be optimistic
25 Women Leaders in UK Healthcare (part 2)

13. SORAYA BEKKALI. Gene therapy pioneer. Cell and gene therapy is definitely the most exciting development in biopharma research, promising breakthroughs and even cures for previously untreatable diseases. ... It has brought to market not one but two
Cancer immunotherapy: What's on the horizon?

antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party
Deal Watch January 2018

pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... DLBCL = diffuse large B-cell lymphoma. BTK = Bruton's
Pharma deals in April 2015

MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1). ... its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

Highlights in haematologic malignancy from ASH 2018

refractory diffuse large B-cell lymphoma. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Content Editor - Biotechnology: Salary TBC

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Account Management: Competitive Salary Offered

Principal Medical Writer: Varies on experience

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....